Antisense technologies: Improvement through novel chemical modifications

European Journal of Biochemistry

Volumn 270, Issue 8, 2003, Pages 1628-1644

  Kurreck, Jens ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Antisense oligonucleotides; Deoxyribozymes; DNA enzymes; Locked nucleic acids; Peptide nucleic acids; Phosphorothioates; Ribozymes; RNA interference; Small interfering RNA

Indexed keywords

ALICAFORSEN; ANGIOZYME; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AVI 4126; AVI 4557; COMPLEMENTARY RNA; EPI 2010; FOMIVIRSEN; GENE EXPRESSION MODULATOR 231; GENE EXPRESSION MODULATOR 92; GTI 2040; GTI 2051; HEPTAZYME; HERZYME; ISIS 104838; ISIS 14803; ISIS 2503; ISIS 3521; MESSENGER RNA; MG 98; OBLIMERSEN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; RIBONUCLEASE H; RIBOSE; RIBOZYME; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ASTHMA; BINDING AFFINITY; BINDING SITE; CATALYSIS; CELL TRANSPORT; CELLULAR DISTRIBUTION; CHEMICAL MODIFICATION; CLINICAL TRIAL; COLORECTAL CANCER; DNA MICROARRAY; DRUG BLOOD LEVEL; DRUG HALF LIFE; GENE EXPRESSION; GENOMICS; HEPATITIS C; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN RNA BINDING; RETINITIS; REVIEW; RNA CLEAVAGE; RNA TRANSLATION; VIRUS INHIBITION;

ANIMALS; BASE SEQUENCE; CLINICAL TRIALS; HUMANS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGORIBONUCLEOTIDES, ANTISENSE; RNA, CATALYTIC; RNA, SMALL INTERFERING; TISSUE DISTRIBUTION;

HEPATITIS C VIRUS; MAMMALIA;

EID: 0037733977     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1033.2003.03555.x     Document Type: Review

References (131)

1. Zamecnik, P.C. & Stephenson, M.L. (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl Acad. Sci. USA 75, 280-284.
2. Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K. & Tuschl, T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498.
3. Bennett, C.F. & Cowsert, L.M. (1999) Antisense oligonucleotides as a tool for gene functionalization and target validation. Biochim. Biophys. Acta 1489, 19-30.
4. Driver, S.E., Robinson, G.S., Flanagan, J., Shen, W., Smith, L.E.H., Thomas, D.W. & Roberts, P.C. (1999) Oligonucleotide-based inhibition of embryonic gene expression. Nat. Biotechnol. 17, 1184-1187.
5. Lebedeva, I. & Stein, C.A. (2001) Antisense oligonucleotides: promise and reality. Ann. Rev. Pharmacol. Toxicol. 41, 403-419.
6. Stein, C.A. (2001) The experimental use of antisense oligonucleotides: a guide for the perplexed. J. Clin. Invest. 108, 641-644.
7. Sohail, M. & Southern, E.M. (2000) Selecting optimal antisense reagents. Adv. Drug Deliv. Rev. 44, 23-34.
8. Ho, S.P., Britton, D.H.O., Stone, B.A., Behrens, D.L., Leffet, L.M., Hobbs, F.W., Millaer, J.A. & Trainor, G.L. (1996) Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucleic Acids Res. 24, 1901-1907.
9. Ho, S.P., Bao, Y., Lesher, T., Malhorta, R., Ma, L.Y., Fluharty, S.J. & Sakai, R.R. (1998) Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat. Biotechnol. 16, 59-63.
10. Matveeva, O., Felden, B., Audlin, S., Gesteland, R.F. & Atkins, J.F. (1997) A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures. Nucleic Acids Res. 25, 5010-5016.
11. Kurreck, J., Bieber, B., Jahnel, R. & Erdmann, V.A. (2002) Comparative study of DNA enzymes and ribozymes against the same full-length messenger RNA of the vanilloid receptor subtype I. J. Biol. Chem. 277, 7099-7107.
12. Milner, N., Mir, K.U. & Southern, E.M. (1997) Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat. Biotechnol. 15, 537-541.
13. Scherr, M. & Rossi, J.J. (1998) Rapid determination and quantitation of the accessibility to native RNAs by antisense oligodeoxynucleotides in murine cell extracts. Nucleic Acids Res. 26, 5079-5085.
14. Tu, G.C., Cao, Q.N., Zhou, F. & Isarel, Y. (1998) Tetranucleotide GGGA motif in primary RNA transcripts. Novel target sites for antisense design. J. Biol. Chem. 273, 25125-25131.
15. Bost, F., McKay, R., Dean, N.M., Potapova, O. & Mercola, D. (2000) Antisense methods for discrimination of phenotypic properties of closely related gene products: Jun kinase family. Methods Enzymol. 314, 342-362.
16. Dove, A. (2002) Antisense and sensibility. Nat. Biotechnol. 20, 121-124.
17. Herdewijn, P. (2000) Heterocyclic modifications of oligonucleotides and antisense technology. Antisense Nucleic Acids Drug Dev. 10, 297-310.
18. Eckstein, F. (2000) Phosphorothioate oligonucleotides: What is their origin and what is unique about them? Antisense Nucleic Acids Drug Dev. 10, 117-121.
19. De Clercq, E., Eckstein, F. & Merigan, T.C. (1969) Interferon induction increased through chemical modification of a synthetic polyribonucleotide. Science 165, 1137-1139.
20. Matsukura, M., Shinozuka, K., Zon, G., Mitsuya, H., Reitz, M., Cohen, J.S. & Broder, S. (1987) Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl Acad. Sci. USA 84, 7706-7719.
21. Campbell, J.M., Bacon, T.A. & Wickstrom, E. (1990) Oligodeoxynucleoside phosphotothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J. Biochem. Biophys. Methods 20, 259-267.
22. Phillips, M.I. & Zhang, Y.C. (2000) Basic principles of using antisense oligonucleotides in vivo. Methods Enzymol. 313, 46-56.
23. Kurreck, J., Wyszko, E., Gillen, C. & Erdmann, V.A. (2002) Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res. 30, 1911-1918.
24. Crooke, S.T. (2000) Progress in antisense technology: the end of the beginning. Methods Enzymol. 313, 5-45.
25. Brown, D.A., Kang, S.-H., Gryaznov, S.M., DeDionisio, L., Heidenreich, O., Sullivan, S., Xu, X. & Neerenberg, M.I. (1994) Effects of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem. 43, 26801-26805.
26. Guvakova, M.A., Yakubov, L.A., Vlodavsky, I., Tonkinson, J.L. & Stein, C.A. (1995) Phosphorothioate Oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270, 2620-2627.
27. Rockwell, P., O'Connor, W., King, K., Goldstein, N.I., Zhang, L.M. & Stein, C.A. (1998) Cell-surface pertubations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc. Natl Acad. Sci. USA 94, 6523-6528.
28. Levin, A.A. (1999) A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1489, 69-84.
29. Crooke, S.T., Lemonidis, K.M., Neilson, L., Griffey, R., Lesnik, E.A. & Monia, B.P. (1995) Kinetic characteristics of Escherichia coli RNase Hl: cleavage of various antisense oligonucleotide-RNA duplexes. Biochem. J. 312, 599-608.
30. Zamaratski, E., Pradeepkumar, P.I. & Chattopadhyaya, J. (2001) A critical survey of the structure-function of the antisense oligo/RNA heteroduplex as substrate for RNase H. J. Biochem. Biophys. Methods 48, 189-208.
31. Baker, B.F., Lot, S.S., Condon, T.P., Cheng-Flournoy, S., Lesnik, E.A., Sasmor, H.M. & Bennett, C.F. (1997) 2′-O-(2-methoxy) ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem. 272, 11994-12000.
32. Sierakowska, H., Sambade, M., Agrawal, S. & Kole, R. (1996) Repair of thalassemic human β-globin mRNA in mammalian cells by antisense oligonucleotides. Proc. Natl Acad. Sci. USA 93, 12840-12844.
33. Monia, B.P., Lesnik, E.A., Gonzales, C., Lima, W.F., McGee, D., Guinosso, C.J., Kawasaki, A.M., Cook, P.D. & Freier, S.M. (1993) Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268, 14514-14522.
34. Wu, H., Lima, W.F. & Crooke, S.T. (1999) Properties of cloned and expressed human RNase H1. J. Biol. Chem. 274, 28270-28278.
35. Nielsen, P.E. (1999) Antisense properties of peptide nucleic acid. Methods Enzymol. 313, 156-164.
36. Elayadi, A.N. & Corey, D.R. (2001) Application of PNA and LNA oligomers to chemotherapy. Curr. Opinion Invest. Drugs 2, 558-561.
37. Braasch, D.A. & Corey, DR. (2002) Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochemistry 41, 4503-4509.
38. Nielsen, P.E., Egholm, R.H., Berg, R.H. & Buchardt, O. (1991) Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254, 1497-1500.
39. Sazani, P., Gemignani, F., Kang, S.H., Maier, M.A., Manohara, M., Persmark, M., Bortner, D. & Kole, R. (2002) Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol. 20, 1228-1233.
40. Gryaznov, S. & Chen, J.-K. (1994) Oligodeoxyribonucleotide N3′ → P5′ Phosphoroamidates: Synthesis and hybridization properties. J. Am. Chem. Soc. 116, 3143-3144.
41. Skorski, T., Perrotti, D., Nieborowsa-Skorska, M., Gryaznov, S. & Calabretta, B. (1997) Antileukemia effect of c-myc N3′ → P5′ phosphoroamidate antisense oligonucleotides in vivo. Proc. Natl Acad. Sci. USA 94, 3966-3971.
42. Faira, M., Spiller, D.G., Dubertret, C., Nelson, J.S., White, M.R.H., Scherman, D., Hélène, C. & Giovannangeli, C. (2001) Phosphoroamidate oligonucleotides as potent antisense molecules in cells and in vivo. Nat. Biotechnol. 19, 40-44.
43. Damha, M.J., Wilds, C.J., Noronha, A., Bruckner, I., Borkow, G., Arion, D. & Parniak, M.A. (1998) Hybrids of RNA and arabinonucleic acids (ANA and FANA) are substrates of ribonuclease H. J. Am. Chem. Soc. 120, 12976-12977.
44. Lok, C.-N., Viazovkina, E., Min, K.-L., Nagy, E., Wilds, C.J., Damha, M.J. & Parniak, M.A. (2002) Potent gene-specific inhibitory properties of mixed-backbone antisense oligonucleotides comprised of 2′-deoxy-2′-fluoro-D-arabinose and 2′deoxyribose nucleotides. Biochemistry 41, 3457-3467.
45. Braasch, D.A. & Corey, D.R. (2001) Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem. Biol. 8, 1-7.
46. Ørum, H. & Wengel, J. (2001) Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development. Curr. Opinion Mol. Ther. 3, 239-243.
47. Koshkin, A.A., Singh, S.K., Nielsen, P., Rajwanshi, V.K., Kumar, R., Meldgaard, M., Olsen, C.E. & Wengel, J. (1998) LNA (locked nucleic acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecendented nucleic acid recognition. Tetrahedron 54, 3607-3630.
48. Koshkin, A.A., Rajwanshi, V.K. & Wengel, J. (1998) Novel convenient syntheses of LNA [2.2.1] bicyclo nucleosides. Tetrahedron Lett. 39, 4381-4384.
49. Obika, S., Nanbu, D., Hari, Y., Andoh, J.-I., Morio, K.-I., Doi, T. & Imanishi, T. (1998) Stability and structural features of the duplexes containing nucleoside analogues with fixed N-type conformation, 2′-O,4′-C-methyleneribonucleosides. Tetrahedron Lett. 39, 5401-5404.
50. Bondensgaard, K., Petersen, M., Singh, S.K., Rajwanshi, V.K., Kumar, R., Wengel, J. & Jacobsen, J.P. (2000) Structural studies of LNA: RNA duplexes by NMR: Conformations and implications for RNase H activity. Chem. Eur. J. 6, 2687-2695.
51. Arzumanov, A., Walsh, A.P., Rajwanshi, V.K., Kumar, R., Wengel, J. & Gait, M.J. (2001) Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2′-O-methyl/LNA oligoribonucleotides. Biochemistry 40, 14645-14654.
52. Braasch, D.A., Liu, Y. & Corey, D.R. (2002) Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design. Nucleic Acids Res. 30, 5160-5167.
53. Wahlestedt, C., Salmi, P., Good, L., Kela, J., Johnsson, T., Hökfelt, T., Broberger, C., Porreca, F., Lai, J., Ren, K., Ossipov, M., Koshkin, A., Jakobsen, N., Skouv, J., Ørum, H., Jacobson, M.H. & Wengel, J. (2000) Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl Acad. Sci. USA 97, 5633-5638.
54. Elayadi, A.N., Braasch, D.A. & Corey, D.R. (2002) Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase. Biochemistry 41, 9973-9981.
55. Fluiter, K., ten Asbroek, A.L.M.A., de Wissel, M., Jakobs, M.E., Wissenbach, M., Olsson, H., Olsen, O., Ørum, H. & Baas, F. (2003) In vivo tumor growth inhibition and biodistribution studies of Locked Nucleic Acid (LNA) antisense oligonucleotides. Nucleic Acids Res. 31, 953-962.
56. Heasman, J. (2002) Morpholino oligos: making sense of antisense? Dev. Biol. 243, 209-214.
57. Nasevicius, A. & Ekker, S.C. (2000) Effective targeted gene 'knockdown' in zebrafish. Nat. Genet. 26, 216-220.
58. Lacerra, G., Sierakowska, H., Carestia, C., Fucharoen, S., Summerton, J., Weller, D. & Kole, R. (2000) Restoration of hemogloblin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc. Natl Acad. Sci. USA 97, 9591-9596.
59. Wang, J., Verbeure, B., Luyten, I., Lescrinier, E., Froeyen, M., Hendrix, C., Rosemeyer, H., Seela, F., van Aerschot, A. & Herdewijn, P. (2000) Cyclohexene Nucleic Acids (CeNA): Serum stable oligonucleotides that activate RNase H and increase duplex stability with complementary RNA. J. Am. Chem. Soc. 122, 8595-8602.
60. Verbeure, B., Lescrinier, E., Wang, J. & Herdewijn, P. (2001) RNase H mediated cleavage of RNA by cyclohexene nucleic acid (CeNA). Nucleic Acids Res. 29, 4941-4947.
61. Steffens, R. & Leumann, C.J. (1997) Tricyclo DNA: a phosphodiester-backbone based DNA analog exhibiting strong base-pairing properties. J. Am. Chem. Soc. 119, 11548-11549.
62. Renneberg, D. & Leumann, C.J. (2002) Watson-Crick base-pairing properties of tricyclo-DNA. J. Am. Chem. Soc. 124, 5993-6002.
63. Renneberg, D., Bouliong, E., Reber, U., Schümperli, D. & Leumann, C.J. (2002) Antisense properties of tricyclo-DNA. Nucleic Acids Res. 30, 2751-2757.
64. Hughes, M.D., Hussain, M., Nawaz, Q., Sayyed, P. & Akhtar, S. (2001) The cellular delivery of antisense oligonucleotides and ribozymes. Drug Discovery Today 6, 303-315.
65. Liang, L., Liu, D.-P. & Liang, C.-C. (2002) Optimizing the delivery systems of chimeric RNA/DNA oligonucleotides: Beyond general oligonucleotide transfer. Eur. J. Biochem. 269, 5753-5758.
66. Becker, D.L., Lin, J.S. & Green, C.R. (1999) Pluronic gel as a means of antisense delivery. In Antisense Technology in the Central Nervous System (Leslie, R.A., Hunter, A.J. & Robertson, H.A., eds), pp. 147-157. Oxford University Press, New York, USA.
67. Santiago, F.S., Lowe, H.C., Kavurma, M.M., Chesterman, C.N., Baker, A., Atkins, D.G. & Khachigian, L.M. (1999) New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat. Med. 5, 1264-1269.
68. Khachigian, L.M., Fahmy, R.G., Zhang, G., Bobryshev, Y.V. & Kaniaros, A. (2002) c-Jun regulates vascular smooth muscle cell growth and neointima formation after arterial injury. J. Biol. Chem. 277, 22985-22991.
69. Oehlke, J., Birth, P., Klauschenz, E., Wiesner, B., Beyermann, M., Oksche, A. & Bienert, M. (2002) Cellular uptake of antisense oligonucleotides after complexing or conjugation with cell-penetrating model peptides. Eur. J. Biochem. 269, 4015-4032.
70. Shi, N., Boado, R.J. & Pardridge, W.M. (2000) Antisense imaging of gene expression in the brain in vivo. Proc. Natl Acad. Sci. USA 97, 14709-14714.
71. Lai, J., Gold, M.S., Kim, C.-S., Bian, D., Ossipov, M.H., Hunter, J.C. & Porreca, F. (2002) Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium chanel, NaVl.8. Pain 95, 143-152.
72. Marwick, C. (1998) First 'antisense' drug will treat CMV retinitis. J. Am. Med. Assoc. 280, 871.
73. Niiler, E. (2001) Analysts: Isis-Lilly deal validates antisense. Nat. Biotechnol. 19, 898-899.
74. Dove, A. (2000) Isis and antisense face crucial test without Novartis. Nat. Biotechnol. 18, 19.
75. Tamm, I., Dörken, B. & Hartmann, G. (2001) Antisense therapy in oncology: new hope for an old idea? Lancet 358, 489-497.
76. Sandrasagra, A., Leonard, S.A., Tang, L., Teng, K., Li, Y., Ball, H.B., Mannion, J.C. & Nyce, J.W. (2002) Discovery and development of respirable antisense therapeutics for asthma. Antisense Nucleic Acid Drug Dev. 12, 177-181.
77. Luger, S.M., O'Brian, S.G., Ratajczak, J., Ratajczak, M.Z., Mick, R., Stadtmauer, E.A., Nowell, P.C., Goldman, J.M. & Gewirtz, A.M. (2002) Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study. Blood 99, 1150-1158.
78. Wang, H., Cai, Q., Zeng, X., D Agrawal, S. & Zhang, R. (1999) Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the R1α subunit of protein kinase A after oral administration. Proc. Natl Acad. Sci. USA 96, 13989-13994.
79. Devi, G.R. (2002) Prostate cancer: status of current treatments and emerging antisense therapies. Curr. Opin. Mol. Ther. 4, 138-148.
80. Shea-Herbert, B., Pongracz, K., Shay, J.W. & Gryaznov, S.M. (2002) Oligonucleotide N3′ → P5′ phosphoroamidates as efficient telomerase inhibitors. Oncogene 21, 638-642.
81. Opalinska, J.B. & Gewirtz, A.M. (2002) Nucleic acids therapeutics: Basic principles and recent applications. Nat. Rev. Drug Discov. 1, 503-514.
82. Cech, T.R., Zaug, A.J. & Grabowski, P.J. (1981) In vitro splicing of the ribosomal RNA precursor of Tetrahymena: involvement of a guanosine nucleotide in the excision of the intervening sequence. Cell 27, 487-296.
83. Kruger, K., Grabowski, P.J., Zaug, A.J., Sands, J., Gottschling, D.E. & Cech, T.R. (1982) Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell 31, 147-157.
84. Guerrier-Takada, C., Gardiner, K., Marsh, T., Pace, N. & Altman, S. (1983) The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell 35, 849-857.
85. Eckstein, F. & Lilley, D.M.J. (1996) Catalytic RNA. Springer Verlag, Berlin/Heidelberg/New York.
86. James, H.A. & Gibson, I. (1998) The therapeutic potential of ribozymes. Blood 91, 371-382.
87. Sun, L.Q., Cairns, M.J., Saravolac, E.G., Baker, A. & Gerlach, W.L. (2000) Catalytic nucleic acids: from lab to applications. Pharmacol. Rev. 52, 325-347.
88. Jen, K.-Y. & Gewirtz, A.M. (2000) Suppression by targeted disruption of messenger RNA: available options and current strategies. Stem Cells 18, 307-319.
89. Doudna, J.A. & Cech, T.R. (2002) The chemical repertoire of natural ribozymes. Nature 418, 222-228.
90. Uhlenbeck, O.C. (1987) A small catalytic oligoribonucleotide. Nature 328, 596-600.
91. Haseloff, J. & Gerlach, W.L. (1988) Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 334, 585-591.
92. Kore, A.R., Vaish, N.K., Kutzke, U. & Eckstein, F. (1998) Sequence specificity of the hammerhead ribozyme revisited; the NHH rule. Nucleic Acids Res. 26, 4110-4120.
93. Jarvis, T.C., Wincott, F.E., Alby, L.J., McSwiggen, J.A., Beigelman, L., Gustofson, J., DiRenzo, A., Levy, K., Arthur, M., Matulic-Adamic, J., Karpeisky, A., Gonzalez, C., Woolf, T.M., Usman, N. & Stinchcomb, D.T. (1996) Optimizing the cell efficacy of synthetic ribozymes. J. Biol. Chem. 271, 29107-29112.
94. Scherr, M., Reed, M., Huang, C.-F., Riggs, A.D. & Rossi, J.J. (2000) Oligonucleotide scanning of native mRNAs in extracts predicts intracellular ribozyme efficiency: ribozyme-mediated reduction of the murine DNA methyltransferase. Mol. Ther. 2, 26-38.
95. Lieber, A. & Strauss, M. (1995) Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library. Mol. Cell Biol. 15, 540-551.
96. Bramlage, B., Luzi, E. & Eckstein, F. (2000) HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture. Nucleic Acids Res. 28, 4059-4067.
97. Pierce, M.L. & Ruffner, D.E. (1998) Construction of a hammerhead ribozyme library: towards the identification of optimal target sites for antisense-mediated gene inhibition. Nucleic Acids Res. 26, 5093-5101.
98. Michienzi, A. & Rossi, J.J. (2001) Intracellular application of ribozymes. Methods Enzymol. 341, 581-596.
99. Sullenger, B.A. & Gilboa, E. (2002) Emerging clinical applications of RNA. Nature 418, 252-258.
100. Beigelman, L., McSwiggen, J.A., Draper, K.G., Gonzalez, C., Jensen, K., Karpeisky, A.M., Modak, A.S., Matulic-Adamic, J., DiRenzo, A.B., Haeberli, P., Sweedler, D., Tracz, D., Grimm, S., Wincott, F.E., Thackaray, V.G. & Usman, N. (1995) Chemical modification of hammerhead ribozymes. J. Biol. Chem. 270, 25702-25708.
101. Vaish, N.K., Heaton, P.A., Fedorva, O. & Eckstein, F. (1998) In vitro selection of a purine nucleotide-specific hammerhead-like ribozyme. Proc. Natl Acad. Sci. USA 95, 2158-2162.
102. 2+ concentration. Nucleic Acids Res. 27, 2400-2407.
103. Eckstein, F., Kore, A.R. & Nakamaye, K.L. (2001) In vitro selection of hammerhead ribozyme sequence variants. Chem. Biochem. 2, 629-635.
104. Zinnen, S.P., Domenico, K., Wilson, M., Dickinson, B.A., Beaudry, A., Molker, V., Daniher, A.T., Burgin, A. & Beigelman, L. (2002) Selection, design and characterization of a new potentially therapeutic ribozyme. RNA 8, 214-228.
105. Santoro, S.W. & Joyce, G.F. (1997) A general purpose RNA-cleaving DNA enzyme. Proc. Natl Acad. Sci. USA 94, 4262-4266.
106. Joyce, G.F. (2001) RNA cleavage by the 10-23 DNA Enzyme. Methods Enzymol. 341, 503-517.
107. Sun, L.-Q., Cairns, M.J., Gerlach, W.L., Witherington, C., Wang, L. & King, A. (1999) Suppression of smooth muscle cell proliferation by a c-myc RNA-cleaving deoxyribozyme. J. Biol. Chem. 274, 17236-17241.
108. Zaborowska, Z., Fürste, J.-P., Erdmann, V.A. & Kurreck, J. (2002) Sequence requirements in the catalytic core of the ′10-23′ DNA enzyme. J. Biol. Chem. 277, 40617-40622.
109. Flory, C.M., Pavco, P.A., Jarvis, T.C., Lesch, M.E., Wincott, F.E., Beigelman, L., Hunt, S.W. III & Schrier, D.J. (1996) Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery of the knee joint. Proc. Natl Acad. Sci. USA 93, 754-758.
110. Aigner, A., Fischer, D., Merdan, T., Brus, C., Kissel, T. & Czubayko, F. (2002) Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Ther. 9, 1700-1707.
111. Usman, N. & Blatt, L.M. (2000) Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J. Clin. Invest. 106, 1197-1202.
112. Wright, L. & Kearney, P. (2001) Current status of ribozymes as gene therapy agents for cancer. Cancer Invest. 19, 495-509.
113. Macejak, D., Jensen, K.L., Jamison, S., Domenico, K., Roberts, E.C., Chaudhary, N., von Carlowitz, I., Bellon, L., Tong, M.J., Conrad, A., Pavco, P.A. & Blatt, L.M. (2000) Inhibition of Hepatitis C Virus (HCV)-RNA-dependent translation and replication of a chimeric HCV Poliovirus using synthetic stabilized ribozymes. Hepatology 31, 769-776.
114. Fire, A., Xu, S.Q., Montgomery, M.K., Kostas, S.A., Driver, S.E. & Mello, C.C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811.
115. Zamore, P.D. (2001) RNA interference: listening to the sound of silence. Nat. Struct. Biol. 8, 746-750.
116. Hannon, G. (2002) RNA interference. Nature 418, 244-251.
117. McManus, M.T. & Sharp, P.A. (2002) Gene silencing in mammals by small interfering RNAs. Nat. Rev. 3, 737-747.
118. Yu, J.-Y., DeRuiter, S.L. & Turner, D.L. (2002) RNA interference by expression of short-interfering and hairpin RNAs in mammalian cells. Proc. Natl Acad. Sci. USA 99, 6047-6052.
119. Paddison, P.J., Caudy, A.A., Bernstein, E., Hannon, G.J. & Conklin, D.S. (2002) Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 16, 948-958.
120. Tuschl, T. (2002) Expanding small RNA interference. Nat. Biotechnol. 20, 446-448.
121. Sui, G., Soohoo, C., Affar, E.B., Gay, F., Shi, Y., Forrester, W.C. & Shi, Y. (2002) A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl Acad. Sci. USA 99, 5515-5520.
122. Paul, C.P., Good, P.D., Winer, I. & Engelke, D.R. (2002) Effective expression of small interfering RNA in human cells. Nat. Biotechnol. 20, 505-508.
123. Brummelkamp, T.R., Bernards, R. & Agami, R. (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550-553.
124. Lee, N.S., Dohjima, T., Bauer, G., Li, H., Li, M.-J., Ehsani, A., Salvaterra, P. & Rossi, J. (2002) Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol. 20, 500-505.
125. Miyagishi, M. & Taira, K. (2002) U6 promotor-driven siRNA with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nat. Biotechnol. 20, 497-500.
126. Amarzguioui, M., Holen, T., Babaie, E. & Prydz, H. (2003) Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 31, 589-595.
127. McCaffrey, A.P., Meuse, L., Pham, T.-T.T., Conklin, D.S., Hannon, G.J. & Kay, M.A. (2002) RNA interference in adult mice. Nature 418, 38-39.
128. Lewis, D.L., Hagstrom, J.E., Loomis, A.G., Wolff, J.A. & Herweijer, H. (2002) Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. 32, 107-108.
129. Song, E., Lee, S.-K., Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P. & Lieberman, J. (2003) RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9, 347-351.
130. Brummelkamp, T.R., Bernards, R. & Agami, R. (2002) Stable suppression of tumorgenicity by virus-mediated RNA interference. Cancer Cell 2, 243-247.
131. Xia, H., Mao, Q., Paulson, H. & Davidson, B.L. (2002) siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. 20, 1006-1010.